Xcell Therapeutics엑셀세라퓨틱스
373110 · KOSDAQ · ₩373110 · 엑셀세라퓨틱스
- Market cap
- ₩17B
- Enterprise value
- ₩18B
- P/E
- —
- P/B
- 4.0×
- Dividend yield
- 0.0%
- ROE
- −262.7%
- Net margin
- −260.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−58.3% from the high
₩951Today: ₩972 – ₩1,039₩2,395
Returns
- 1W−4.6%
- 1M−0.1%
- 3M−8.9%
- 6M−40.6%
- YTD−39.9%
- 1Y−53.8%
- Volume today
- 80,621
- 1.2× the 20-day average
- Traded today
- ₩81M
- Listed shares
- 17,294,394
- EPS (12 months)
- −₩657
- Earnings yield −65.8%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 47 of 100 (50 is a normal day for this stock).
- MomentumFlat-1.4% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Xcell Therapeutics stock overview
Xcell Therapeutics (엑셀세라퓨틱스, KRX: 373110) is listed on KOSDAQ, in the Biotech & Pharma sector. Excel Therapeutics develops and manufactures cell culture media, the essential materials used to develop and produce cell and gene therapies, and is expanding into other applications such as cultivated meat media, cosmetic ingredients for cell regeneration, artificial blood production media, organoid media for animal-free testing, and animal vaccine production media. Its shares closed at ₩998 on Oct 29, 2026, down 4.04% on the day, giving it a market value of ₩17B.
Key facts
- Market cap
- ₩17B
- Sector
- Biotech & Pharma
- Latest price change
- −4.04%
- As of
- Oct 29, 2026
- Main business
- Excel Therapeutics develops and manufactures cell culture media, the essential materials used to develop and produce cell and gene therapies, and is expanding into other applications such as cultivated meat media, cosmetic ingredients for cell regeneration, artificial blood production media, organoid media for animal-free testing, and animal vaccine production media.
Quick answers about Xcell Therapeutics
- What does Xcell Therapeutics do?
- Excel Therapeutics develops and manufactures cell culture media, the essential materials used to develop and produce cell and gene therapies, and is expanding into other applications such as cultivated meat media, cosmetic ingredients for cell regeneration, artificial blood production media, organoid media for animal-free testing, and animal vaccine production media. The company operates a GMP manufacturing facility in Yongin, Gyeonggi Province, and sells domestically and overseas, with exports in 2025 recorded in its sales breakdown.
- What is the market cap of Xcell Therapeutics?
- The market capitalisation of Xcell Therapeutics was ₩17B at the close on Oct 29, 2026.
- Who are the largest shareholders of Xcell Therapeutics?
- According to the latest official filings, the largest reported holders are Lee Ui-il (18.65%, as of Oct 27, 2026); Jung Hae-min (0.39%, as of Oct 23, 2026); Lee Ju-yeon (0.13%, as of Nov 7, 2025).
- When is the next earnings report from Xcell Therapeutics?
- Korean companies rarely announce results dates in advance. Based on when Xcell Therapeutics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Excel Therapeutics develops and manufactures cell culture media, the essential materials used to develop and produce cell and gene therapies, and is expanding into other applications such as cultivated meat media, cosmetic ingredients for cell regeneration, artificial blood production media, organoid media for animal-free testing, and animal vaccine production media. The company operates a GMP manufacturing facility in Yongin, Gyeonggi Province, and sells domestically and overseas, with exports in 2025 recorded in its sales breakdown.
Written by AI from the company's latest annual report.
- Korean name
- 엑셀세라퓨틱스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이의일
- Founded
- Sep 2015
- Listed
- Jul 2024
- Listed shares
- 17,294,394
- Fiscal year ends
- Month 12
- Website
- www.xcell.media
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- 5%+ holding reportOct 27, 2026
- Insider shareholding reportOct 23, 2026
- Other Market Notice (Potential Designation as Administrative Issue – Market Capitalization Below ₩20B)Oct 12, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsSep 11, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Xcell Therapeutics / 엑셀세라퓨틱스 / 373110 / KRX:373110
Source: KRX statistical information